212 related articles for article (PubMed ID: 29298867)
1. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.
Richards DB; Cookson LM; Barton SV; Liefaard L; Lane T; Hutt DF; Ritter JM; Fontana M; Moon JC; Gillmore JD; Wechalekar A; Hawkins PN; Pepys MB
Sci Transl Med; 2018 Jan; 10(422):. PubMed ID: 29298867
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.
Richards DB; Cookson LM; Berges AC; Barton SV; Lane T; Ritter JM; Fontana M; Moon JC; Pinzani M; Gillmore JD; Hawkins PN; Pepys MB
N Engl J Med; 2015 Sep; 373(12):1106-14. PubMed ID: 26176329
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.
Wechalekar A; Antoni G; Al Azzam W; Bergström M; Biswas S; Chen C; Cheriyan J; Cleveland M; Cookson L; Galette P; Janiczek RL; Kwong RY; Lukas MA; Millns H; Richards D; Schneider I; Solomon SD; Sörensen J; Storey J; Thompson D; van Dongen G; Vugts DJ; Wall A; Wikström G; Falk RH
BMC Cardiovasc Disord; 2022 Feb; 22(1):49. PubMed ID: 35152886
[TBL] [Abstract][Full Text] [Related]
4. An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study.
Richards D; Millns H; Cookson L; Lukas MA
Orphanet J Rare Dis; 2022 Jul; 17(1):259. PubMed ID: 35810311
[TBL] [Abstract][Full Text] [Related]
5. The Pentraxins 1975-2018: Serendipity, Diagnostics and Drugs.
Pepys MB
Front Immunol; 2018; 9():2382. PubMed ID: 30459761
[TBL] [Abstract][Full Text] [Related]
6. Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis.
Sahota T; Berges A; Barton S; Cookson L; Zamuner S; Richards D
CPT Pharmacometrics Syst Pharmacol; 2015 Feb; 4(2):e15. PubMed ID: 26225229
[TBL] [Abstract][Full Text] [Related]
7. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.
Bodin K; Ellmerich S; Kahan MC; Tennent GA; Loesch A; Gilbertson JA; Hutchinson WL; Mangione PP; Gallimore JR; Millar DJ; Minogue S; Dhillon AP; Taylor GW; Bradwell AR; Petrie A; Gillmore JD; Bellotti V; Botto M; Hawkins PN; Pepys MB
Nature; 2010 Nov; 468(7320):93-7. PubMed ID: 20962779
[TBL] [Abstract][Full Text] [Related]
8. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis.
Gillmore JD; Tennent GA; Hutchinson WL; Gallimore JR; Lachmann HJ; Goodman HJ; Offer M; Millar DJ; Petrie A; Hawkins PN; Pepys MB
Br J Haematol; 2010 Mar; 148(5):760-7. PubMed ID: 20064157
[TBL] [Abstract][Full Text] [Related]
9. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
Pepys MB; Herbert J; Hutchinson WL; Tennent GA; Lachmann HJ; Gallimore JR; Lovat LB; Bartfai T; Alanine A; Hertel C; Hoffmann T; Jakob-Roetne R; Norcross RD; Kemp JA; Yamamura K; Suzuki M; Taylor GW; Murray S; Thompson D; Purvis A; Kolstoe S; Wood SP; Hawkins PN
Nature; 2002 May; 417(6886):254-9. PubMed ID: 12015594
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits in vivo.
Al-Shawi R; Tennent GA; Millar DJ; Richard-Londt A; Brandner S; Werring DJ; Simons JP; Pepys MB
Open Biol; 2016 Feb; 6(2):150202. PubMed ID: 26842068
[TBL] [Abstract][Full Text] [Related]
11. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value.
Jager PL; Hazenberg BP; Franssen EJ; Limburg PC; van Rijswijk MH; Piers DA
J Nucl Med; 1998 Apr; 39(4):699-706. PubMed ID: 9544684
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component.
Hawkins PN; Lavender JP; Pepys MB
N Engl J Med; 1990 Aug; 323(8):508-13. PubMed ID: 2377176
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1.
Borthwick NJ; Lane T; Moyo N; Crook A; Shim JM; Baines I; Wee EG; Hawkins PN; Gillmore JD; Hanke T; Pepys MB
PLoS One; 2018; 13(5):e0197299. PubMed ID: 29772028
[TBL] [Abstract][Full Text] [Related]
14. Prospective and serial study of primary amyloidosis with serum amyloid P component scintigraphy: from diagnosis to prognosis.
Hachulla E; Maulin L; Deveaux M; Facon T; Blétry O; Vanhille P; Wechsler B; Godeau P; Levesque H; Hatron PY; Huglo D; Devulder B; Marchandise X
Am J Med; 1996 Jul; 101(1):77-87. PubMed ID: 8686719
[TBL] [Abstract][Full Text] [Related]
15. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis.
Hawkins PN; Wootton R; Pepys MB
J Clin Invest; 1990 Dec; 86(6):1862-9. PubMed ID: 2254450
[TBL] [Abstract][Full Text] [Related]
16. Monitoring systemic amyloidosis using MRI measurements of the extracellular volume fraction.
Campbell-Washburn AE; Price AN; Ellmerich S; Simons JP; Al-Shawi R; Kalber TL; Ghatrora R; Hawkins PN; Moon JC; Ordidge RJ; Pepys MB; Lythgoe MF
Amyloid; 2013 Jun; 20(2):93-8. PubMed ID: 23621497
[TBL] [Abstract][Full Text] [Related]
17. Novel methods to determine complement activation in human serum induced by the complex of Dezamizumab and serum amyloid P.
Ma J; Liu Q; White JR
J Biol Chem; 2021 Oct; 297(4):101136. PubMed ID: 34461096
[TBL] [Abstract][Full Text] [Related]
18. Drug targets for amyloidosis.
Kolstoe SE; Wood SP
Biochem Soc Trans; 2010 Apr; 38(2):466-70. PubMed ID: 20298204
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic performance and prognostic value of extravascular retention of 123I-labeled serum amyloid P component in systemic amyloidosis.
Hazenberg BP; van Rijswijk MH; Lub-de Hooge MN; Vellenga E; Haagsma EB; Posthumus MD; Jager PL
J Nucl Med; 2007 Jun; 48(6):865-72. PubMed ID: 17504868
[TBL] [Abstract][Full Text] [Related]
20. Interaction of serum amyloid P component with hexanoyl bis(D-proline) (CPHPC).
Kolstoe SE; Jenvey MC; Purvis A; Light ME; Thompson D; Hughes P; Pepys MB; Wood SP
Acta Crystallogr D Biol Crystallogr; 2014 Aug; 70(Pt 8):2232-40. PubMed ID: 25084341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
